(Q38696763)

English

Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): A systematic review of randomized controlled trials

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 September 2017

Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): A systematic review of randomized controlled trials (English)

1 reference

Europe PubMed Central

5 September 2017

0 references

0 references

0 references

0 references

rheumatoid arthritis

0 references

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

J Ablin

3

0 references

author name string

M-A Fitzcharles

1

1 reference

Europe PubMed Central

5 September 2017

C Baerwald

2

1 reference

Europe PubMed Central

5 September 2017

W Häuser

4

1 reference

Europe PubMed Central

5 September 2017

publication date

14 January 2016

1 reference

Europe PubMed Central

5 September 2017

1 reference

Europe PubMed Central

5 September 2017

30

1 reference

Europe PubMed Central

5 September 2017

47-61

1 reference

Europe PubMed Central

5 September 2017

1

1 reference

Europe PubMed Central

5 September 2017

https://scigraph.springernature.com/pub.10.1007/s00482-015-0084-3

0 references

Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

The endocannabinoid system and its therapeutic exploitation

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

Don't middle your MIDs: regression to the mean shrinks estimates of minimally important differences.

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

The dilemma of medical marijuana use by rheumatology patients

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

The endocannabinoid system and pain

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

Review of pharmacological therapies in fibromyalgia syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

Cannabinoid receptor localization in brain

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

Amygdala activity contributes to the dissociative effect of cannabis on pain perception

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo.

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

Fibromyalgia: Moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

"Evidence" in chronic pain--establishing best practice in the reporting of systematic reviews

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

[Opioids in chronic osteoarthritis pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration].

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

Nabilone for the treatment of pain in fibromyalgia

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

Association of herbal cannabis use with negative psychosocial parameters in patients with fibromyalgia

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

Systematic review with meta-analysis: cytokines in fibromyalgia syndrome.

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

Fibromyalgia: a stress disorder? Piecing the biopsychosocial puzzle together

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

Opioids for chronic musculoskeletal pain: putting patient safety first

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

Tetrahydrocannabinol (Delta 9-THC) Treatment in Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter Survey

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

Cannabinoids for Medical Use

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

Imputing response rates from means and standard deviations in meta-analyses

1 reference

https://api.crossref.org/works/10.1007%2FS00482-015-0084-3

21 January 2018

Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/26767993

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anticonvulsants for fibromyalgia

1 reference

https://pubmed.ncbi.nlm.nih.gov/26767993

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Methodenreport der aktualisierten Leitlinie „Langzeitanwendung von Opioiden bei nicht-tumorbedingten Schmerzen – LONTS“

1 reference

https://pubmed.ncbi.nlm.nih.gov/26767993

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Opioids in chronic low back pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration]

1 reference

https://pubmed.ncbi.nlm.nih.gov/26767993

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain--a randomized controlled trial]

1 reference

https://pubmed.ncbi.nlm.nih.gov/26767993

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?

1 reference

https://pubmed.ncbi.nlm.nih.gov/26767993

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risks associated with the non-medicinal use of cannabis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26767993

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy, Tolerability, and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/26767993

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The medicinal use of cannabis in the UK: results of a nationwide survey.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26767993

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expanding medical marijuana access in Canada: considerations for the rheumatologist

1 reference

https://pubmed.ncbi.nlm.nih.gov/26767993

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adverse health effects of marijuana use

1 reference

https://pubmed.ncbi.nlm.nih.gov/26767993

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00482-015-0084-3

1 reference

Europe PubMed Central

5 September 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

5 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38696763&oldid=1778387696"